Hearing Loss

Neurology·MeSH: Hearing Loss

Prevalence

5000.0 / 100K

Incidence

400.0 / 100K/yr

18 drugs in development·10 companies·7 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
esteem fi-amei	Envoy Medical Inc. (COCH)

Phase 3(1)

Drug	Company
Zonisamide 100Mg Cap	UNITED THERAPEUTICS Corp (UTHR)

Phase 2(2)

Drug	Company
cgf166	GENVEC INC (GNVC)
oto-413	OTONOMY, INC. (OTIC)

Phase 1(2)

Drug	Company
db-020	Decibel Therapeutics, Inc. (DBTX)
Intracochlear application of VSF1.01	Accustem Sciences Inc. (ACUT)

Preclinical(11)

Drug	Company
aav.103	Decibel Therapeutics, Inc. (DBTX)
aav.104	Decibel Therapeutics, Inc. (DBTX)
aav.105	Decibel Therapeutics, Inc. (DBTX)
acclaim ci	Envoy Medical Inc. (COCH)
ak-otof	Akouos, Inc. (AKUS)
db-oto	Decibel Therapeutics, Inc. (DBTX)
gjb2 gene therapy	APPLIED GENETIC TECHNOLOGIES CORP (AGTC)
oto-510	OTONOMY, INC. (OTIC)
oto-6xx	OTONOMY, INC. (OTIC)
oto-825	OTONOMY, INC. (OTIC)
resonance	Lineage Cell Therapeutics, Inc. (LCTX)

Phase 1/Phase 2(1)

Drug	Company
db-oto	REGENERON PHARMACEUTICALS, INC. (REGN)

BioSniper tracks 18 drugs in development for Hearing Loss across 10 companies.

There are 7 clinical trials targeting Hearing Loss tracked by BioSniper.

The estimated prevalence of Hearing Loss is approximately 5000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.